Press Releases

Date Title
Toggle Summary Faheem Hasnain joins Kura Oncology's Board of Directors
LA JOLLA, April 27, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company’s board of
Toggle Summary Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan
LA JOLLA, March 30, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by University of Michigan researchers in the
Toggle Summary Kura Oncology Announces License Agreement with Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger
LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.